Sales & Marketing News | pharmaphorum

News

Farxiga back on level pegging in heart failure

The FDA has approved AstraZeneca’s SGLT2 inhibitor Farxiga as a treatment candidate for all patients with heart failure, putting the drug back in contention with rival Jar

News

FDA kicks off review of Roche’s Vabysmo in RVO

Roche could be just months away from a third indication for its eye drug Vabysmo that could accelerate its already fast growth in the US.

News

Baxter will sell biopharma unit to investors for $4.25bn

Baxter has reached an agreement to sell its contract development and manufacturing organisation (CDMO) business to a pair of private equity companies, raising $4.25 billio

News

Securing Market Access to Medicines for England, Ireland, Sc...

The PM Society Market Access Interest Group (MAIG) is gearing up to host its next in-person meeting on Tuesday, May 23rd, at the prestigious Royal Society of Medicine in London.

News

Novo Nordisk taps brakes on Wegovy as demand soars

Novo Nordisk has said it will temporarily reduce production of the lower starting doses of its weight-loss drug Wegovy, as demand for the therapy continues to challenge it

News

J&J sets top price for consumer health unit Kenvue’s IPO

Johnson & Johnson’s consumer health unit Kenvue looks set to raise $3.8 billion in an upsized initial public offering (IPO), valuing the business at around $41 billion

Farxiga back on level pegging in heart failure

FDA kicks off review of Roche’s Vabysmo in RVO

Baxter will sell biopharma unit to investors for $4.25bn

Securing Market Access to Medicines for England, Ireland, Sc...

Novo Nordisk taps brakes on Wegovy as demand soars

J&J sets top price for consumer health unit Kenvue’s IPO

Pfizer cues up vitiligo filing for Litfulo after phase 3 win

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks